At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma
In Brief
A clinical study evaluating Epoetin Alfa, Exercise, and 7 other interventions for Multiple Myeloma. Completed, enrolled 120 participants across 1 site.
Detailed Summary
The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training for patients being treated with high-dose chemotherapy and autologous peripheral bloodstem cell transplantation (PBSC T) for multiple myeloma. The endpoints for the study included the number of attempts at and total number of days of stem cell collection, number of RBC and platelet transfusions during the transplantation period, time-to-recovery after transplantation, and response to intensive therapy for multiple myeloma.
Study Details
Timeline
Interventions
Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
A home-based individualized exercise program that incorporated aerobic and strength resistance training.
Standard PBSCT for multiple myeloma
RBC Transfusion was administered as needed
Fifty percent of the participants received 400 mg daily
Patients who received thalidomide also received prophylactic low molecular weight heparin
Platelet transfusions were administered as needed
Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
RBC Transfusion was administered as needed
Fifty percent of participants received 400 mg daily
Patients who received thalidomide also received prophylactic low molecular weight heparin
Platelet transfusions were administered as needed
Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma